News
EDIT
3.356
+1.69%
0.056
Weekly Report: what happened at EDIT last week (0413-0417)?
Weekly Report · 2d ago
Editas publishes corporate presentation on in vivo gene editing, LDL-C lowering candidate EDIT-401
PUBT · 5d ago
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
NASDAQ · 04/15 15:30
Editas Medicine price target raised to $15 from $13 at Evercore ISI
TipRanks · 04/13 13:45
Weekly Report: what happened at EDIT last week (0406-0410)?
Weekly Report · 04/13 09:09
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
NASDAQ · 04/08 15:30
Editas Medicine replaces Ernst & Young with PwC as auditor for 2026
Reuters · 04/07 20:29
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
NASDAQ · 04/07 12:55
JonesTrading Sticks to Their Buy Rating for Editas Medicine (EDIT)
TipRanks · 04/06 20:45
Weekly Report: what happened at EDIT last week (0330-0403)?
Weekly Report · 04/06 09:09
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector
Barchart · 03/31 07:07
Weekly Report: what happened at EDIT last week (0323-0327)?
Weekly Report · 03/30 09:09
USPTO Ruling Impacts Editas Medicine CRISPR IP Position
TipRanks · 03/27 12:52
Editas Announced USPTO Reaffirms Broad's CRISPR Patent Rights
NASDAQ · 03/27 12:18
Editas Medicine Says USPTO Upholds PTAB Ruling Favoring Broad Institute In CRISPR Patent Interference
Benzinga · 03/27 11:16
Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents
TipRanks · 03/27 11:15
Editas Medicine Sees USPTO Reaffirm Broad Institute's CRISPR Patent Priority
Benzinga · 03/27 11:05
EDITAS MEDICINE INC - USPTO REAFFIRMS PTAB DECISION FAVORING BROAD INSTITUTE IN CRISPR/CAS9 PATENT INTERFERENCE
Reuters · 03/27 11:02
Editas Medicine patent interference narrows; USPTO reaffirms PTAB ruling favoring Broad Institute
Reuters · 03/27 11:01
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Barchart · 03/27 06:00
More
Webull provides a variety of real-time EDIT stock news. You can receive the latest news about Editas Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.